Tafasitamab binds CD19 on B cells; its Fc engages CD32A (Fc gamma receptor IIA) on effector cells to trigger ADCC/ADCP that kills CD19+ cells. CD32A+ cells serve as effectors and are not targeted or killed by the drug.